Results 61 to 70 of about 11,886 (196)

Eccrine Squamous Syringometaplasia Mimicking Acute Cutaneous GVHD in a Pediatric HSCT Recipient: Case Report and Brief Review of the Indexed Literature

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Eccrine squamous syringometaplasia (ESS) is an uncommon reactive alteration of eccrine ducts, most often reported in oncologic and transplant settings, where it may clinically mimic acute cutaneous graft‐versus‐host disease (GVHD). We describe a 3‐year‐old boy with chronic granulomatous disease who developed a diffuse erythematous eruption 6 ...
Benedetta Galli   +5 more
wiley   +1 more source

Eculizumab in pregnancy: a narrative overview [PDF]

open access: yes, 2019
Pregnancy can be a dangerous trigger for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), or hemolysis, elevated liver enzymes and low platelet (HELLP) syndrome. Due to the possibility of several serious
Tufano A.   +5 more
core   +1 more source

Thrombotic microangiopathy after kidney transplantation successfully treated with eculizumab: A case report

open access: yesTransplantation Reports, 2018
Background: Transplantation-associated thrombotic microangiopathy (TA-TMA) is relatively rare and may cause graft failure. Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the alternative complement pathway, resulting in TMA ...
Tomoko Kawanishi   +11 more
doaj   +1 more source

Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy

open access: yesKidney Medicine, 2020
In patients with pregnancy-associated complement gene variant–mediated thrombotic microangiopathy (cTMA), terminal complement blockade is used for treatment of cTMA flares during pregnancy or following delivery.
Natalja Haninger-Vacariu   +9 more
doaj   +1 more source

Inborn errors of immunity in children with neuroinflammation

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract Inborn errors of immunity (IEIs), an expanding group of monogenic disorders with diverse clinical manifestations, are increasingly recognized to include neuroinflammatory disease. Examples of diseases included under this umbrella are Aicardi–Goutières syndrome, deficiency of adenosine deaminase 2, familial haemophagocytic lymphohistiocytosis ...
Eppie M Yiu   +5 more
wiley   +1 more source

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations [PDF]

open access: yes, 2016
Fatimah Al-Ani,1 Ian Chin-Yee,1 Alejandro Lazo-Langner1,2 1Department of Medicine, Division of Hematology, 2Department of Epidemiology and Biostatistics, Western University, London, ON, Canada Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a ...
Chin-Yee I, Lazo-Langner A, Al-Ani F
core  

Eculizumab improves fatigue in refractory generalized myasthenia gravis [PDF]

open access: yes, 2019
Purpose: To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue ...
Ferreira, Luciana   +497 more
core   +6 more sources

Pegcetacoplan Delivers Real‐World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real‐World Clinical and Patient‐Reported Outcomes

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Aims Paroxysmal nocturnal haemoglobinuria (PNH) is an ultra‐rare, acquired, non‐malignant haematological disorder that, if left untreated, can lead to significant morbidity. This systematic literature review (SLR) summarized real‐world evidence (RWE) for pegcetacoplan, a complement 3/3b inhibitor (C3i) available since 2021.
Juan Carlos Vallejo Llamas   +4 more
wiley   +1 more source

Mapping of C5‐Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition

open access: yesImmunology, EarlyView.
We identify four distinct C5 inhibitory epitopes, including two novel antibodies that selectively block membrane attack complex (MAC) assembly while preserving C5 cleavage and C5a generation. These findings establish selective MAC inhibition as a new therapeutic strategy for complement‐mediated diseases.
Rebekah Sian Cooke   +5 more
wiley   +1 more source

Eculizumab in kidney diseases [PDF]

open access: yes
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement ...
Fatemeh Pour-Reza-Gholi, Sara Assadiasl
core   +1 more source

Home - About - Disclaimer - Privacy